The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Open accessAbstract
Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 long-term responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibition of the PI3K/AKT/mTOR pathway improves the efficacy of anti-PD-1 and anti-CTLA-4 antibodies in mouse models [226,230,231].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [231]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Cited by
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Brain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 722
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Hara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., Eichhorn, S. W., Greenwald, A. C., Kinker, G. S., Rodman, C., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.002 · Cited by 593
“To that end, we explored a recently published bulk RNA-seq dataset of PD-1-inhibitor-treated glioblastoma (Zhao et al., 2019).”
Metadata
- Authors
- Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J., Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend, A. M., & Rabadan, R.
- Affiliations
- Columbia University (US)
- Columbia University Irving Medical Center (US)
- University of North Carolina at Chapel Hill (US)
- Northwestern University (US)
- Oregon Health & Science University (US)
- Corresponding author
- Iwamoto, Fabio M.
- Sonabend, Adam M.
- ORCID
- Zhao, Junfei
- Chen, Andrew X.
- Gartrell, Robyn D.
- Aparicio, Luis
- Bordbar, Darius
- Shan, David
- Samanamud, Jorge
- Mahajan, Aayushi
- Orenbuch, Rose
- Yamaguchi, Jonathan T.
- Cloney, Michael
- Horbinski, Craig
- Lukas, Rimas V.
- Raizer, Jeffrey
- Rae, Ali I.
- Yuan, Jinzhou
- Canoll, Peter
- Bruce, Jeffrey N.
- Saenger, Yvonne M.
- Sims, Peter
- Iwamoto, Fabio M.
- Sonabend, Adam M.
- Rabadan, Raul
- Venue
- Nature Medicine
- Published
- 2019-02-11
- Volume
- 25
- Issue
- 3
- Pages
- 462-469
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6810613
- OpenAlex
- W2911871569
- Cited by
- 903
- References
- 60
- Citations by year
- 2026: 73 · 2025: 119 · 2024: 125 · 2023: 119 · 2022: 165 · 2021: 146 · 2020: 110 · 2019: 45
- FWCI
- 49.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (UL1TR001422, DP5OD021356, UL1TR001873, TL1TR001875)
- Directorate for Mathematical and Physical Sciences
- National Cancer Institute (R01CA185486, R01CA179044, U54CA193313, P50CA221747, P30CA060553)
- National Institute of General Medical Sciences (T32GM007367)
- National Institute of Neurological Disorders and Stroke (R01NS102669, R01NS103473)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- glioblastoma, anti-PD-1 therapy, immune checkpoint inhibitors, nivolumab, pembrolizumab, treatment response prediction, PTEN mutation, MAPK pathway alterations, tumor clonal evolution, neoantigens, tumor microenvironment, immune cell infiltration, patient stratification
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Adult, Aged, Brain Neoplasms, Female, Glioblastoma, Humans, Immune Tolerance, Longitudinal Studies, Male, Middle Aged, Mutation, T-Lymphocytes, Treatment Outcome, Gene Expression Profiling, Genomics, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Young Adult, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. https://app.cochat.ai/papers/10.1038/s41591-019-0349-y
- The paper
- Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., . . . Rabadan, R. (2019). Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine. https://doi.org/10.1038/s41591-019-0349-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.